NASDAQ:DBTX

Decibel Therapeutics Competitors

$10.54
-0.08 (-0.75 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.45
Now: $10.54
$11.06
50-Day Range
$10.56
MA: $14.81
$19.90
52-Week Range
$10.41
Now: $10.54
$24.39
Volume29,945 shs
Average Volume192,106 shs
Market Capitalization$262.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Decibel Therapeutics (NASDAQ:DBTX) Vs. FDMT, CNTB, ITOS, PHVS, GRCL, and PHAR

Should you be buying DBTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Decibel Therapeutics, including 4D Molecular Therapeutics (FDMT), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), iTeos Therapeutics (ITOS), Pharvaris B.V. (PHVS), Gracell Biotechnologies (GRCL), and Pharming Group (PHAR).

Decibel Therapeutics (NASDAQ:DBTX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Decibel Therapeutics and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Decibel Therapeutics and 4D Molecular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Decibel Therapeutics and 4D Molecular Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
4D Molecular Therapeutics01202.67

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. 4D Molecular Therapeutics has a consensus target price of $45.50, suggesting a potential upside of 20.72%. Given Decibel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decibel Therapeutics is more favorable than 4D Molecular Therapeutics.

Summary

Decibel Therapeutics beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.

Decibel Therapeutics (NASDAQ:DBTX) and Connect Biopharma Holdings Limited American Depositary Shares (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Decibel Therapeutics and Connect Biopharma Holdings Limited American Depositary Shares' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/A

Valuation & Earnings

This table compares Decibel Therapeutics and Connect Biopharma Holdings Limited American Depositary Shares' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Decibel Therapeutics and Connect Biopharma Holdings Limited American Depositary Shares, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
Connect Biopharma Holdings Limited American Depositary Shares0000N/A

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. Given Decibel Therapeutics' higher probable upside, analysts clearly believe Decibel Therapeutics is more favorable than Connect Biopharma Holdings Limited American Depositary Shares.

Summary

Decibel Therapeutics beats Connect Biopharma Holdings Limited American Depositary Shares on 2 of the 2 factors compared between the two stocks.

Decibel Therapeutics (NASDAQ:DBTX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Decibel Therapeutics and iTeos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
iTeos TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Decibel Therapeutics and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
iTeos TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Decibel Therapeutics and iTeos Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
iTeos Therapeutics00503.00

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. iTeos Therapeutics has a consensus target price of $49.40, suggesting a potential upside of 82.90%. Given Decibel Therapeutics' higher probable upside, equities analysts plainly believe Decibel Therapeutics is more favorable than iTeos Therapeutics.

Decibel Therapeutics (NASDAQ:DBTX) and Pharvaris B.V. (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Decibel Therapeutics and Pharvaris B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
Pharvaris B.V.N/AN/AN/A

Earnings and Valuation

This table compares Decibel Therapeutics and Pharvaris B.V.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
Pharvaris B.V.N/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Decibel Therapeutics and Pharvaris B.V., as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
Pharvaris B.V.01302.75

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. Pharvaris B.V. has a consensus target price of $47.50, suggesting a potential upside of 67.73%. Given Decibel Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Decibel Therapeutics is more favorable than Pharvaris B.V..

Summary

Decibel Therapeutics beats Pharvaris B.V. on 3 of the 3 factors compared between the two stocks.

Decibel Therapeutics (NASDAQ:DBTX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Decibel Therapeutics and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Decibel Therapeutics and Gracell Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Decibel Therapeutics and Gracell Biotechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
Gracell Biotechnologies00403.00

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. Gracell Biotechnologies has a consensus target price of $34.50, suggesting a potential upside of 155.56%. Given Decibel Therapeutics' higher probable upside, equities analysts plainly believe Decibel Therapeutics is more favorable than Gracell Biotechnologies.

Summary

Decibel Therapeutics beats Gracell Biotechnologies on 2 of the 2 factors compared between the two stocks.

Decibel Therapeutics (NASDAQ:DBTX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Decibel Therapeutics and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel TherapeuticsN/AN/AN/A
Pharming GroupN/AN/AN/A

Earnings and Valuation

This table compares Decibel Therapeutics and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel TherapeuticsN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Decibel Therapeutics and Pharming Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Therapeutics00503.00
Pharming Group0000N/A

Decibel Therapeutics presently has a consensus target price of $28.80, suggesting a potential upside of 173.24%. Given Decibel Therapeutics' higher probable upside, equities analysts plainly believe Decibel Therapeutics is more favorable than Pharming Group.

Summary

Decibel Therapeutics beats Pharming Group on 2 of the 2 factors compared between the two stocks.


Decibel Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01-11.1%$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00Analyst Downgrade
Gap Down
PHAR
Pharming Group
0.0$13.26-0.0%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44-2.2%$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48-1.4%$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13-4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89-8.0%$0.00N/A0.00High Trading Volume
Gap Down
SCPS
Scopus BioPharma
1.4$7.57-6.2%$0.00N/A0.00Gap Down
VECT
VectivBio
0.0$24.23-29.8%$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.